The overall response rate was 68% with 21% complete responses (CR) and 47% partial responses (PR) (see figure 1). Prior treatment with bortezomib had no effect on response rate.r A transient increase in the absolute lymphocyte count was observed in 34% of patients and typically resolved within a median of 8.0 weeks.r
Figure 1: Response to therapy
© New England Journal of Medicine 2013
The median follow up in the initial paper was 15.3 monthsr and was extended to 26.7 months in the second publication.r At the later follow up, the median treatment duration was reported as 8.3 months with 46% treated for >12 months and 22% for >24 months. The median PFS was 13 months and median OS was 22.5 months. The 2 year PFS was 31% and OS was 47% (see figure 2).
Figure 2: Time-to-event end points
© Blood 2015